LGVN Longeveron Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1721484 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-18.9%
TTM net income YoY-4.9%
TTM EPS YoY134.5%
Revenue 3-yr CAGR15.0%
Net income 3-yr CAGR—
Margins
Gross margin66.4%
Operating margin-2,020.8%
Net margin-1,921.7%
FCF margin-1,560.1%
EBITDA margin-1,952.1%
Returns
ROE-305.1%
ROA-162.4%
ROIC (approx.)—
Asset turnover0.08x
Leverage & solvency
Liabilities / assets60.8%
Debt / equity0.00x
Current ratio1.25x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.80x
Accruals ratio-31.8%
Payout ratio—
Capex / revenue14.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $1.20M | $2.39M |
| Cost of revenue | $396,000 | $508,000 |
| Gross profit | $803,000 | $1.88M |
| R&D expense | $12.04M | $8.14M |
| SG&A expense | $12.05M | $10.27M |
| Operating income | -$23.29M | -$16.52M |
| Income tax | $0 | $0 |
| Net income | -$22.70M | -$15.97M |
| EBITDA | -$22.49M | -$15.82M |
| EPS (basic) | -1.29 | -2.62 |
| EPS (diluted) | -1.29 | -2.62 |
| Weighted avg. shares (diluted) | 17.58B | 9.41B |
| Balance sheet | ||
| Cash & equivalents | $4.66M | $19.23M |
| Short-term investments | — | $0 |
| Receivables | $104,000 | $84,000 |
| Current assets | $5.45M | $19.62M |
| PP&E, net | $1.84M | $2.45M |
| Intangibles | $2.29M | $2.40M |
| Total assets | $10.26M | $25.56M |
| Current liabilities | $4.09M | $2.58M |
| Total liabilities | $4.59M | $3.67M |
| Shareholders' equity | $5.67M | $21.89M |
| Cash flow statement | ||
| Operating cash flow | -$18.64M | -$13.87M |
| Capital expenditure | $245,000 | $655,000 |
| Free cash flow | -$18.89M | -$14.52M |
| Investing cash flow | -$595,000 | -$640,000 |
| Financing cash flow | $4.67M | $28.79M |
| Depreciation & amortization | $800,000 | $700,000 |
| Stock-based compensation | $1.68M | $2.33M |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.